Articles

A new study published on bmj.com questions the value of blood glucose monitoring among patients with well-controlled, non-insulin dependent (type 2) diabetes. See Publishers Note.

Transition Therapeutics Announces Results of 6-Month study with Their E1-INT Drug Final results from exploratory Phase IIa Clinical Trial in type 2 diabetes patients after once a day injections for 28 days and then followed for 6 months, lead to sustained reductions in blood glucose levels for the next 5 months.

Walk two miles and call me in the morning. That’s what doctors could soon prescribe if the new leaders of two major medical groups have their way.

After the first of the year, the A1c results will probably get reported to patients as an average blood glucose. Will this will help the 75% of diabetics who don’t know what an A1c test is? It might just make it even more confusing for the patient.

Preclinical data suggests a long-acting formulation of native, human GLP-1 can promote the growth of insulin producing cells (beta cells) in a type 1 diabetes animal model.

Fructose in sodas and other beverages — but not glucose — can set patients on the fast track to atherosclerosis, investigators here reported.

The prevalence of diabetes of all types in the U.S. has risen by about 5% annually since 1990, keeping pace with the fattening of America, reported CDC investigators.

Type 2 diabetes patients taught to titrate their own insulin detemir (Levemir) dose may equal or exceed the results that physicians achieve, researchers reported….

A new study concludes that patients with type 2 diabetes 30 years of age and older who are receiving glucose-reducing treatment should also receive prompt intensive prophylactic treatment for cardiovascular disease.

First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes.